Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation

Gene Therapy

Volumn 12, Issue 3, 2005, Pages 238-245

  Schauber Plewa, C ^a,b   Simmons, A ^a   Tuerk, M J ^a   Pacheco, C D ^a,c   Veres, G ^a,d  

^a CELL GENESYS INC   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d GÉNÉTHON   (France)

Author keywords

Complement; DAF CD55; gp64; Lentivirus; MCP CD46

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; LENTIVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; THROMBOSPONDIN;

ARTICLE; BACULOVIRUS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DOG; DONOR; GENE EXPRESSION; HUMAN; IMMUNOPRECIPITATION; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; RODENT; SENSITIVITY ANALYSIS; SEROLOGY; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INACTIVATION;

ANIMALS; COMPLEMENT INACTIVATOR PROTEINS; DOGS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; RATS; RATS, INBRED STRAINS; VESICULAR STOMATITIS-INDIANA VIRUS;

ANIMALIA; LENTIVIRUS; RODENTIA; UNIDENTIFIED BACULOVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 13544253713     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302399     Document Type: Article

References (36)

1. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991; 65: 1202-1207.
2. Burns JC et al. Vesicular stomatitis virus G protein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
3. Schauber CA et al. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restricted against hematopoietic cell types in vitro. Gene Therapy 2004; 11: 266-275.
4. Kumar M, Bradow BP, Zimmerberg J. Large-scale production of pseudotyped lentiviral vectors using baculovirus gp64. Hum Gene Ther 2003; 14: 67-77.
5. Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43: 99-112.
6. DePolo NJ et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218-222.
7. Takeuchi Y, Porter C, Strahan K. Sensitization of cells and retroviruses to human serum by alpha(1-3)galactosyltransferase. Nature 1996; 379: 85-88.
8. Takeuchi Y, Liong SH, Bieniasz PD. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J Virol 1997; 71: 6174-6178.
9. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cells. J Virol 1994; 68: 8001-8007.
10. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7: 1095-1101.
11. Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved stability. Virology 1996; 218: 290-295.
12. Rollins SA, Birks CW, Squinto SP, Rother RP. Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996; 7: 619-626.
13. Sandrin V et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823-832.
14. Kost TA, Condreay JP. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 2002; 20: 173-180.
15. Hofmann C, Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Therapy 1998; 5: 531-536.
16. Huser A, Rudolph M, Hofmann C. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol 2001; 19: 451-455.
17. Marchal I, Jarvis DL, Cacan R, Verbert A. Glycoproteins of insect cells: sialylated or not? Biol Chem 2001; 382: 151-159.
18. Beebe DP, Cooper NR. Neutralization of vesicular stomatitis virus (VSV) by human complement required a natural IgM antibody present in human serum. J Immunol 1981; 126: 1562-1568.
19. Welsh RMJ, O'Donnell CL, Reed DJ, Rother RP. Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72 4650-4656.
20. Cooper NR, Jensen FC, Welsh RMJ, Oldstone MB. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976; 144: 970-984.
21. Miyao Y et al. FUT-175, a synthetic inhibitor of the complement pathway protects against the inactivation of infectious retroviruses by human serum. Hum Gene Ther 1997; 8: 1575-1583.
22. Bartholomew RM, Esser AF. Mechanism of antibody-independent inactivation of the first component of complement (C1) on retrovirus membranes. Biochemistry 1980; 19: 2846-2853.
23. Uthaisangsook S et al. Innate immunity and its role against infections. Ann Allergy Asthma Immunol 2002; 88: 253-254.
24. Fujita T et al. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166: 1221-1228.
25. Oglesby TJ et al. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175: 1547-1551.
26. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478-3483.
27. Townsend K et al. Adaptation of a lentiviral vector producer cell line to reduced-serum, suspension culture for large-scale production. Mol Ther 2004; 9 (Suppl. 1) Abstract #82, S33.
28. Spitzer D, Hauser H, Wirth D. Complement-protected amphotropic retroviruses from murine packaging cells. Hum Gene Ther 1999; 10: 1893-1902.
29. Ochsenbein AF et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286: 2156-2159.
30. Saifuddin M et al. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78: 1907-1911.
31. Montefiori DC et al. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994; 205: 82-92.
32. Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995; 25: 285-290.
33. Saifuddin M et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995; 182: 501-509.
34. Dull T et al. A third generation lentiviral vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
35. Follenzi A et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
36. Finer MH et al. Kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43-50.